Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
From GTBP (Oxis) 10-Q, 2018-09-30, page 21
On February 15, 2017, MultiCell Immunotherapeutics, or MultiCell, filed an arbitration proceeding against us with the American Health Lawyers Association, Claim #3821. MultiCell is seeking $207,783 plus interest and costs of arbitration pursuant to alleged contract rights against us under a research agreement between MultiCell and us. Following a hearing held September 1, 2017, the arbitrator awarded MultiCell the payment amount of $207,783 plus interest in the amount of $34,699. On September 8, 2018, an agreement was reached between the Company and Multicell whereby the Company paid Multicell $100,000 in cash and agreed to issue 75,000 shares of Common Stock in full settlement of this matter.
Does the technology of Alliance Pharmaceutical Corp. ("Alliance"), and Astral, Inc. just go away? Time is irrelevant as well as phone numbers.
Their subsidiary was called Xenogenics.
Not the same as Xenotech which Andrew Parkinson was involved with.
Twitter waking up... whatever that means
https://twitter.com/search?q=%24mcet&src=typeahead_click&f=live
Ask Travis Huff at La Jolla Cove Investors.
Telephone: 415-409-8703
Email: travis@ljcinvestors.com
Looks like I tempted the fate sisters but in my favor. See y’all. It was a good 15 years
Mcetdreamer and TPX —-> keep posting. There is nothing else going on with this company so why not.
I just want it hit .0004 on the bid. Probably unlikely but who knows...
Yeah same here.... many bag holdings in my inventory playing “the pennies”.
Speaking of old news, might as well talk about SYBIOL....
EXTEN INDUSTRIES, INC.
RESEARCH & DEVELOPMENT
Growth Stock for Today's Investors
State of the art liver support technology...
Imagine a device that can do for liver failure what dialysis does for kidney failure. A device that would remove toxins from the blood, create essential blood clotting factors, aid in digestion, and perform a myriad of other liver functions. For years researchers worldwide have searched for a way to replicate the functions of the body's most complex organ, the liver.
Exten Industries, Inc., through its Xenogenex subsidiary, has created such a device. Known as SYBIOL (synthetic bio-liver), the device operates external to the body, doing for the liver what dialysis machines do for people with kidney disease--and more. So critical to life are these liver functions that patients experiencing liver failure usually die within 96 hours.
"As the indictions for the liver transplantation have increased and as donor organs have become scarcer, the need for an artificial liver has become more imperative."
John J. Brems, M.D., F.A.C.S. Head, Division of Organ Transplantation Scripps Clinic
YOU ARE VISTOR #since 7-20-96
last updated at 9:59 AM on 8/13/96
MAIN MENU
click topic to go to site:
LIVER DISEASE THE MAGNITUDE OF THE PROBLEM
MARKET FOR SYBIOL DEEMED EXTENSIVE
EXTEN MAKING HEADWAY IN ASIAN, SOUTH PACIFIC AND U.S.MARKETS
SYBIOL EMBODIES SUPERIOR TECHNOLOGY
SYBIOL TECHNOLOGY SUPERIOR TO OTHER CONCEPTS
ALTERNATE APPLICATIONS
PROPECTS FOR THE FUTURE
INVESTMENT FEATURES
PRESS RELEASES AND NEWS ARTICALES
LETTER TO SHAREHOLDERS FROM C.E.O & CHAIRMAN
BIOGRAPHICAL SUMMARY ON C.E.O W. GERALD NEWMIN
JOIN OUR EXTEN MAILING LIST
LIVER DISEASE: THE MAGNITUDE OF THE PROBLEM
In the United States, liver disease accounts for an estimated 40,000+ deaths each year with only 3000 of the 5000 patients registered to receive transplants actually getting them. According to John J. Brems, M.D., FACS Head of the Organ Transplantation Di-vision at Scripps Clinic, approximately 20 percent of patients die while awaiting liver transplantation. An artificial means of supporting hepatic function such as SYBIOL would revolutionize the way patients with liver disease are cared for and save hundre-ds of lives every year.
Because of the extraordinary incidences of liver disease in many foreign countries, Exten has formed a Hong Kong joint venture compant to develop these markets.
click here to go back to main menu
MARKET FOR SYBIOL DEEMED EXTENSIVE
A recent survey estimated the annual market in the U.S. for the SYBIOL device at $75 million and incidental disposals at $ 125 million annually. The largest U.S. market segment, replaceable prepackaged hepatocytes, was estimated to have an annual value between $ 900 million and $ 3.6 billion.
click here to go back to main menu
EXTEN MAKING HEADWAY IN ASIAN, SOUTH PACIFIC AND U.S. MARKETS
Exten received revenues in prior years from other business activities which it no longer conducts. The company is currently focused only on the development of SYBIOL and therefore, produces no revenues at present.
Foreign application are expected to provide the earliest revenues since the regulatory processes differ among countries. Exten already has agreements and a business entity in place to bring SYBIOL to Asia and the South Pacific. Ultimately, the company is expected to develop SYBIOL markets in all continents of the world.
China, the home of one billion people and the highest incidence of liver disorder in the world, has already welcomed SYBIOL for clinical trials in Beijing with expected early commercial sales throughout Asia. In independent Hong Kong, The Chinese University Hospital is currently pressing forward with their own plans for clinical application.
Development of the U.S. market will take longer and will require substantial capital. Initial animal development testing has been successful at St. Louis University and Sciences Center. The pending funding, will be completed and specifically directed toward FDA approval of SYBIOL for clinical application in the U.S.
click here to go back to main menu
SYBIOL EMBODIES SUPERIOR TECHNOLOGY
Basically, SYBIOL consist of:
a system capable of regulating the flow and critical environmental parameters, including oxygenation of healthy pig liver cells(hepatocytes);and
a hollow fiber exchange through which a patient's blood is placed in proximity to the hepatocytes through a semipermeable membrane which is periodically replaced.
The semi -permeable membrane inside the exchange offers a significant advantage over previous artificial liver technology: the holes in the membrane enable the hepatocytes to metabolize wastes in the blood without significant triggering of an immune response. Human antibodies are too large to traverse the membrane, and therefore, the mechanism by which rejection of the pig hepatocytes would occur is minimized.
click here to go back to main menu
SYBIOL TECHNOLOGY SUPERIOR TO OTHER CONCEPTS
Exten's product includes important enhancements: a continuous supply of fresh, healthy hepatocytes; regulation of flows; methods of monitoring and controlling oxygen, temperature and PH levels for the hepatocytes; and the removal of waste products.
Other approaches for external liver support have been studied for years: one approached employs a fiber exchanger much like SYBIOL's but the hepatocytes, rather than being directed through the exchanger, are packed inside, coating the outside of each fiber. How cells in this configuration can be sustained long enough to be useful and cost-effective is unknown.
Another approach packs hepatocytes into the fibers rather than on the outside ; the liver cells are then fed by supplemental nutrients to enable them to work more efficiently. Scaling such a device to human proportions may be technically difficult.
It takes many hours, even days to place enough hepatocytes in either of these exchangers and once filled, they must be preserved in storage which causes substantial loss in the quantity of viable cells. With SYBIOL, there is no lengthy lead time needed; treatment is available to the patient within hours of need and viable hepatocytes can be provided indefinitely.
A different approach to mitigate an immune reaction and to overcome the hepatocyte quantity problem is through the use of liver cells obtained from a human hematoma; such a cancerous line of mature hepatocytes can grow in vitro but, while there may be only small risk of such cells getting into the blood, some cancers are caused by viruses which could cross the membrane. If a patient later receives a transplant, because of the immune suppression needed to prevent organ rejection, they will be especially vulnerable to such pathogens.
Through SYBIOL perfusion, some patients are expected to show sufficient clinical improvement such that transplantation may not only be delayed but ultimately avoided. SYBIOL may provide the necessary liver support while the patient's liver is given an opportunity to increase its functional capacity.
click here to go back to main menu
ALTERNATE APPLICATIONS
Applications for SYBIOL in the U.S. market go considerably beyond liver disease: One of the functions of the liver is to materialize drugs out of the bloodstream, making SYBIOL a potentially vital tool in treating drug overdoses. Furthermore, as drug side effects are often caused by the compounds produced by the liver's reaction to a drug, SYBIOL could well provide pharmaceutical companies a safe, inexpensive way to test new drugs. No need for FDA approval of the latter application is deemed neccessary.
click here to go back to main menu
PROPECTS FOR THE FUTURE
Considering the enormous demand for a device such as SYBIOL and the strategies under implementation to bring it to the world market, Exten is well postitoned for success. Investors can obtain current stock prices quotes from their brokers using the NNOTC Electronic Bulletin Board symbol EXTI.
click here go back to main menu
INVESTMENT FEATURES
Liver disease is the third leading cause of death in the 45 - 65 year old age group in the United States and affects one out of three people in some countries.
Exten's SYBIOL incorporates actual living cells to provide liver functions which no machine can.
SYBIOL's patent-pending technology allows continuous controlled treatment for extended periods and minimizes "possible immune reactions."
click here to go back to main menu
For other resources on liver disease and tranplantation see
AMERICAN LIVER FOUNDATION
TRANSPLANTATION RESOURCES ON THE INTERNET
Direct Inquires to:
Exten Industries Inc.
9625 Black Mountian Road, Ste. 218
San Diego, CA 92126
Tel: (619) 578-9784
Fax:(619) 578-9835
or E-Mail at: EXTIXENO@aol.com
I’m sure Tony Cataldo at GTBP knows
I gave up BB gun fights so I saved one eye.
.0004s showed on level 2. Just saying...
Mentioned on twitter
Muta Elewedu (@Mutairu32459371) Tweeted:
$mcet @ $0.0001 to $0.0003
52 wk high $0.001, low $0.000
Biotech: can it moon again/any recent updates from the company? I dont see any recent news.
Will be taking some.....
Old news screenshot https://t.co/qWYhMOfyrW
$mcet @ $0.0001 to $0.0003
— Muta Elewedu (@Mutairu32459371) December 19, 2020
52 wk high $0.001, low $0.000
Biotech: can it moon again/any recent updates from the company? I dont see any recent news.
Will be taking some.....
Old news screenshot pic.twitter.com/qWYhMOfyrW
I was just looking through that. Thanks!
I guess that’s it then between the two companies. Nothing ever came of the ADC’s combined with GTBPs compounds.
I’m thinking outloud here.... I wonder if any of the MCET (MCIT) ADC technology is in someway still used by GTBP (Oxis Biotechnology). GTBP is on the move.
Well... it’s been building it seems. If it starts hitting .0004’s. Then I’m with you on what your smellin..
Good volume today
I Hadn’t seen the authorized share count change on 12/2/2020 until now. Not that it means anything. I did get the transfer agent change in the mail last year. Thx
Yeah I know.... why? I hit the run back in 2003. Thought it would do it again and slowly acquired too much.
And I do have 60 Million shs
I appreciate your enthusiasm!
I believe those days are gone. That’s why I’m wondering if the volume activity is related to a reverse or eventual rumor of a reverse merger. Like SPRL which went to . 0001 to .004 recently. Another one of my previous bag holdings. What do I know .... nothing.
I guess TPX posted the same info. Sorry for the double post. It brought back memories....
Since it is throwback Friday
https://investorshub.advfn.com/Exten-Industries-BB-EXTI-2081/
Multicell Technologies (EXTI) overview revised 3/24/04 Thanks to RB poster Exten Announces Merger with MultiCell Subsidiary New company name will be MultiCell Technologies, Inc. http://www.sec.gov/Archives/edgar/data/811779/000108638004000013/ext8k032304exh991.htm The Multicell Technologies, Inc. business is built around a revolutionary liver cell lines they have developed and patented. These offer many significant advantages, including they are: 1 - human (as opposed to porcine) liver cells that replicate and function without stimulating an immune response in the host, thereby providing a renewable source of cells to treat liver failure without immune-system side effects. 2 - nontumorigenic (non-cancerous, as opposed to other's cancerous human cell lines) 3 - immortalized (The ability of a genetically engineered cell line to reproduce indefinitely) 4 - fully-functional (as discovered by Pfizer & now, Roche, & as opposed to others, which aren't) 5 - readily available (as opposed to porcine, rat or human liver "slices") 6 - cost-effective (as opposed to porcine, rat or human liver "slices") Here's an overview of what the liver does: http://ragingbull.lycos.com/mboard/boards.cgi?board=EXTI&read=12280 See what the industry is saying about EXTI's cell lines: http://ragingbull.lycos.com/mboard/boards.cgi?board=EXTI&read=17331 http://ragingbull.lycos.com/mboard/boards.cgi?board=EXTI&read=21368 These cell lines are enabling EXTI to enter (and possibly dominate) 4 major markets - I'm listing these in the order I think they will be able to enter the respective markets, starting with the market they are already in: 1 - the $3.7 billion Hepatocyte Test Kit market through their MultiCell subsidiary. Through their world wide marketing and distribution agreement with XenoTech has these test kits on the market today, with their product launched at the ISSX Meeting beginning Oct 12, 2003 and is currently being marketed worldwide. Many expect this cell line to become the gold standard for this market. These cell lines have been validated for this specific purpose by Pfizer - http://home.comcast.net/~dcmack2/ISSXPoster.pdf - who signed a 15 year non-exclusive license for EXTI's cell lines after the validation. This validation was confirmed and extended by Hoffman-LaRoche - http://home.comcast.net/~dcmack2/Roche.html - as well as by XenoTech http://homepage.mac.com/alandail/XenoTech2003.pdf XenoTech saw Pfizer's presentation and from that sought out EXTI to become their manufacturer. That focus enabled us to quickly identify it as a potential breakthrough, which our evaluations verified. Thus XenoTech sought out EXTI and did their own independent testing before signing to be their marketing partner on these cell lines for hepatocyte test kits. The product is now being marketed world wide, starting with 3 important conferences. http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20031010005.... http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20031030005.... Pfizer and XenoTech are also copresenting EXTI's technology on 2-11-04 here: http://www.cbinet.com/events/HB405/day_one.html and again here on 6-15-04: http://www.isciencex.com/DDI-2004%20program%20FINAL.htm and XenoTech is one of the exhibitors as well: http://www.cbinet.com/events/HB405/Sponsors/sponsors.html 2 - the $43 billion Therapeutic Protein Production market through their MultiCell subsidiary. Being fully functional liver cells, they can generate therapeutic proteins with high yield and low cost vs. current methods and even can generate supplies where none exist today. Here are a couple of links with more on Therapeutic Proteins http://ragingbull.lycos.com/mboard/boards.cgi?board=EXTI&read=11379 http://www.multicelltechnologies.com/30/ and here's another potential application: http://ragingbull.lycos.com/mboard/boards.cgi?board=EXTI&read=12227 3 - the $2 billion bioartificial liver market through their Xenogenics subsidiary. Think of it as dialysis for the liver. Again, these fully functional immortalized liver cell lines give EXTI a major advantage in this market. Also, the design of the device is a major advantage as well. The Sybiol is designed with specially patented chambers which allow the cells to circulate for maximum efficiency and even longer utility, reducing costs to hospitals vs. the competition. http://exten.com/exten2/sybiol.htm http://ragingbull.lycos.com/mboard/boards.cgi?board=EXTI&read=11606 http://ragingbull.lycos.com/mboard/boards.cgi?board=EXTI&read=12730 http://ragingbull.lycos.com/mboard/boards.cgi?board=EXTI&read=12266 4 - the $78 billion Liver Stem Cell Transplantation market. The holy grail of liver research - to be able to regenerate damaged liver tissue. EXTI has also been expanding their independent board. Here is news of the latest new board member http://biz.yahoo.com/bw/031124/245268_1.html here's what he had to say Dr. Maggio commented, "Exten Industries' cell-based toxicological and drug screening technologies address certain critical needs among pharmaceutical and biotech companies to make more accurate assessments of the likely success of new drug candidates before they are actually placed into clinical trials. This technology promises to increase the efficiency of drug discovery and save many millions of dollars by reducing the ultimate failure rate in clinical trials, benefiting both drug companies and consumers alike." Here's his company: http://www.cengent.com/corporate_info.html Some more links to look at here's a good post from Scott Brassfield of EXTI: http://ragingbull.lycos.com/mboard/boards.cgi?board=EXTI&read=5678 Here's the unofficial EXTI investor site: http://exti.info/ Here's the official EXTI web site: http://exten.com/ And here's another site with a great collection of EXTI information: http://www.hannibalsweb.com/cgi-bin/hannibalsweb/ikonboard.cgi?s=61740b76cd8a5f990fe222ce30fd4d10;ac.... 3/26/04 update to Multicell/Xenotech Conferences in 2004 Thanks to seatech3 at the EXTI RB thread Conferences/Journals this year (12 and counting) 1. Jan 13, 2004 - Journal of Pharmacology and Experimental Therapeutics http://intl-jpet.aspetjournals.org/cgi/content/abstract/jpet.103.061713v1 Induction of drug metabolizing enzymes and MDR1 using a novel hepatocyte cell line Jessica B Mills 1, Kelly Rose 1, Nalini Sadagopan 1, Jasminder Sahi 1, Sonia M. F. de Morais 1* Pfizer Global Research and Development "Induction of drug metabolizing enzymes and transporters can cause drug-drug interactions and loss of efficacy. In vitro induction studies traditionally use primary hepatocyte cultures and enzyme activity with selected marker compounds. We investigated the use of a novel human hepatocyte clone, the Fa2N-4 cell line, as an alternative reagent, which is readily available and provides a consistent, reproducible system. We used the Invader® assay to monitor gene expression in these cells. This assay is a robust, yet simple, high-throughput system for quantification of mRNA transcripts. CYP1A2, CYP3A4, CYP2C9, UGT1A, and MDR1 transcripts were quantified from total RNA extracts from Fa2N-4 cells treated with a panel of known inducers and compared with vehicle controls. In addition, we used enzyme activity assays to monitor the induction of CYP1A2, CYP2C9, and CYP3A4. The Fa2N-4 cells responded in a similar manner as primary human hepatocytes. Treatment with 10 µM rifampin resulted in increases in CYP3A4 mRNA (17-fold) and activity (6-beta-hydroxytestoterone formation, 9-fold); and in CYP2C9 mRNA (4-fold) and activity (4'-hydroxydiclofenac formation, 2-fold). Treatment with 50 µM beta-naphthoflavone resulted in increases in CYP1A2 mRNA (15-fold) and activity (7-ethoxyresorufin O-dealkylation, 27-fold). UGT1A mRNA was induced by beta-naphthoflavone (2-fold), and MDR1 (P-glycoprotein) mRNA was induced by rifampin (3-fold). These preliminary data using a few prototypical inducers show that Fa2N-4 cells can be a reliable surrogate for primary human hepatocytes, and, when used in conjunction with the Invader® technology, could provide a reliable assay for assessment of induction of drug metabolizing enzymes and transporters." 2. Feb 11, 2004 - Annual Forum on ADME/Tox http://www.cbinet.com/events/HB405/day_one.html 2:15 Induction of Major Cytochrome P450 Enzymes in Immortalized Human Hepatocytes Primary cultures of human hepatocytes are the most suitable test system to evaluate induction of drug metabolizing enzymes by New Chemical Entities (NCEs). The supply of human livers available for support of drug development though is increasingly limited and their response to NCE’s is highly variable due to numerous environmental and genetic factors. Recently, SV40 T Ag-immortalized hepatocytes, Fa2N-4, demonstrated cytochrome P450 (CYP) enzyme’s activity and inducibility, among other characteristics of differentiated liver functions. Since these cells can be cryopreserved and are readily available, they constitute a test system alternative to primary cultures of hepatocytes. This session discusses the data from two independent laboratories who have characterized the activity of multiple CYP in response to prototypical enzyme inducers, which regulate gene expression through distinctive nuclear receptor pathways. • Cultured with a uniquely formulated media, these cells grow and maintain their functions in 96-well plates • Cell culture and LC/MS/MS methods were developed to ascertain inductive potential of NCEs with Fa2N-4 cells Jessica B. Mills, Ph.D., Associate Scientist, Pfizer Inc Andrew Parkinson, Ph.D., President and CEO, XenoTech LLC XenoTech will also sponsor an exhibit at this meeting. 3. IBC's Preclinical Development Forum Feb 23 - 25, 2004 Cambridge, MA XenoTech will sponsor an exhibit at this conference. 4. ISE's 4th International Conference on Early Toxicity Screening Feb 23 - 24, 2004 San Diego, CA Presentation by Dr. Andrew Parkinson, XenoTech CEO Session 2 "Immortalized Hepatocytes: A New In Vitro Approach to Early Induction and Hepatotoxicity Screening XenoTech will also sponsor an exhibit at this conference 5. ECPM Course: Toxicology and Clinical Pharmacology March 8 - 10, 2004 Basel, Switzerland Andrew Parkinson, Ph.D. will lecture on the topic of Drug Metabolism in Health and Disease. 6. Wednesday, March 24, 2004 Society of Toxicology Annual Meeting http://www.toxicology.org/memberservices/meetings/am2004/ 1:30 - 4:30 p.m. - THE USE OF IMMORTALIZED HEPATOCYTES IN METABOLISM AND INDUCTION STUDIES Kevin C. Lyon, XenoTech 7. Cell-Based Assays For HTS May 17-18, 2004, Philadelphia, Pennsylvania Break-Through Technologies 9:55-10:10 Immortalized Hepatocytes: A New In Vitro Approach to Early Compound Screening Andrew Parkinson, Ph.D., Chief Executive Officer, XenoTech, LLC A new human hepatocyte cell line has the potential to solve the problem of supply and inter-individual variability that restrict the use of human hepatocytes for candidate comparisons in preclinical metabolism, toxicity, and induction studies. Its unlimited supply assures long-term reproducibility and scheduling convenience in utilizing this breakthrough technology. 8. May 19(Wed) - 21(Fri), 2004 for 3 days at Tokyo Big Sight, Japan - The 3rd INTERNATIONAL BIO EXPO JAPAN 2004, together with the INTERPHEX JAPAN INTERNATIONAL BIO EXPO JAPAN expands again, welcome some 450 exhibitors, presenting their latest products, technologies and services. Last year, 13,591 professionals visited INTERNATIONAL BIO EXPO JAPAN. It is expected that some 15,000 professionals attend from Japan and all over the world. List of exhibitors includes: XENOTECH LLC 9. June 15, 2004 - 7th International Conference on Drug-Drug Interactions https://www.isciencex.com/DDI-2004%20program%20FINAL.htm 10:30 AM – 11:15 AM Immortalized and Fresh Human Hepatocytes: Use and Performance in Metabolism, Induction and Toxicity Screening (Andrew Parkinson, XenoTech, Lenexa, KS) Human hepatocytes play several key roles in preclinical drug development, including assessment of enzyme induction, cellular toxicity, drug metabolism and species comparisons. This presentation compares fresh and cryopreserved human hepatocytes to a new human hepatocyte cell line that has the potential to solve the problem of supply and variability that restrict the use of human hepatocytes for enzyme induction and other in vitro screening. 11:15 AM – 12:00 PM Predicting Clinical DDI Arising from CYP3A4 Induction Using In Vitro Data: Studies with the Fa2N-4 Immortalized Hepatocyte Line (Sharon L. Ripp, Pfizer Global Research & Development; Groton, CT) The Fa2N-4 human hepatocyte line, when treated with prototypical inducers, shows a robust induction of CYP3A4 mRNA and enzymatic activity. We are examining ways to use this in vitro induction data to predict clinical DDI due to CYP3A4. One possibility is to combine potency and efficacy data from Fa2N-4 cells with efficacious plasma concentrations to assess in vivo induction potential. Studies assessing the validity of this approach using prototypical inducers will be discussed. 10. 7th International ISSX Meeting August 29 - September 2, 2004 Vancouver, BC, Canada Go to ISSX 11. The Seventh Annual International Conference on Drug Metabolism/Applied Pharmacokinetics Devil’s Head Lodge, Merrimac, WI September 13-17, 2004 Wednesday, September 15 9:30 Wine and Cheese Reception Sponsored by Xenotech LLC Lenexa, KS 12. AAPS (November 7 - 11, 2004) http://www.aapspharmaceutica.com/meetings/annualmeet/am04/ XenoTech - booth 202 (at the main entrance)
I guess GTBP spiking helps MCET
I just took a dump of 5.1 M . It felt good.
.0004 today?
Yeah, What is going on? Would the action be typical of a reverse merger play? Not sure on this one.
Ask Jerry
https://twitter.com/jnewmin?s=21
Ask Barbara
https://twitter.com/photashop?s=21
Could be why they went stealth. May be the Emmes group would know and may be there is still connection with Cataldo at GTBP. Just spitballin as I watch time and sales. Is time irrelevant in this case? Where does the intellectual property go?
Scratching my head a little ... I did get a transfer agent letter change and it was for Multicell technologies (MCET) not for MEDS.
Reverse merger maybe. Like SPRL. Dormant for years then slow steady buying from .0001 to .0049. I’ll take it (49x)
Like Chang in his private lab working on MCT-666 that destroys all known viral and bacterial anti bodies. Faris and that dude from Mannkind channeling Hurreggi (sp) to combat liver cancer and Barbara’s sun tan lotion made from leftover Sybiol fluid...
WZ
Well better late than ....
Maybe Ed’s down at the elbow room if he hasn’t filed bankruptcy again.
https://candysdirt.com/2016/07/27/death-dallas-dive-elbow-room-biting-dust-make-room-dental-school/
Hit Barbara up on twitter and see if Gerry is still kicking. I’ve got 65m shares framed maybe I’ll trade it for some her art. Fair deal.
https://twitter.com/photashop/status/1238907598482661391?s=21
Yes very true.
I check still since I’m the greatest bag holder of all time. Just wondering if the change in stock transfer agent will help. I kind’ve chuckled when I got the letter from Equiniti. A pulse ... nah
At least they (mm’s) are consistent. Maybe it’s Newmin .....